Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

46.83 -2.00 (-4.09%)

Streaming Delayed Price Updated: 10:15 AM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

29 30 31 32 33 34 35 36 Next >

Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today ↗

August 05, 2021

Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players.

Via InvestorPlace

Better Buy: Vertex vs. CRISPR ↗

July 31, 2021

Vertex might be undervalued, CRISPR Therapeutics might be overvalued, but both are looking for a home run.

Via The Motley Fool

CRSP Stock: The Good News Goosing CRISPR Therapeutics Shares Today ↗

July 30, 2021

Shares of CRSP stock are rising on Friday after CRISPR Therapeutics provided a positive business update regarding its leading drug candidate.

Via InvestorPlace

Why CRISPR Therapeutics' Stock Is Trading Higher Today ↗

July 30, 2021

CRISPR Therapeutics AG (NASDAQ: CRSP) is trading higher Friday morning after the company announced second-quarter financial results that showed significant improvement year over...

Via Benzinga

Why CRISPR Therapeutics' Stock Is Trading Higher Today ↗

July 29, 2021

CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher after the company reported Q2 earnings per share results of $9.44, up from $(1.30) year-over-year. 'We expect...

Via Benzinga

Crispr Therapeutics Represents the Best of Emerging Biotechnology ↗

July 26, 2021

CRSP stock may end up being a pioneer, or it may fizzle. The timeline until we know is typical of biotech stocks.

Via InvestorPlace

Is CRISPR Therapeutics a Millionaire-Maker Stock? ↗

July 24, 2021

It's already well on its way, but the road ahead will be long.

Via The Motley Fool

Topics Initial Public Offering

3 Things About CRISPR Therapeutics That Smart Investors Know ↗

July 23, 2021

The company is on track to be the first to market with a gene-editing therapy for blood disorders.

Via The Motley Fool

Crispr Therapeutics Has Bullish DNA ↗

July 22, 2021

Crispr Therapeutics isn't without risks, but that shouldn't dissuade investors from a CRSP stock collar purchase for core positioning.

Via InvestorPlace

Can CRISPR Therapeutics Stock Investors Steer Clear of Ethical Concerns? ↗

July 19, 2021

Ethical concerns will likely dog CRISPR Therapeutics stock, especially with the present social awakening.

Via InvestorPlace

Topics Economy

Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week ↗

July 16, 2021

After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.

Via The Motley Fool

Cramer Gives His Opinion On Wynn Resorts, Advanced Micro Devices And More ↗

July 14, 2021

On CNBC's "Mad Money Lightning Round," Jim Cramer said he likes Blackstone Group Inc (NYSE: BX) very much. He keeps buying Wynn Resorts, Limited (NASDAQ: WYNN) for...

Via Benzinga

How Investors Can Own A Piece Of Tesla, Shopify, CRISPR Therapeutics ↗

July 12, 2021

Investing in the ARK Innovation ETF (NYSE:ARKK) is the ...

Via Benzinga

WHO Issues Framework For Governance For Gene Editing Technologies ↗

July 12, 2021

A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or...

Via Benzinga

A Comprehensive Guide To Genomic ETFs ↗

July 11, 2021

Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon...

Via Talk Markets

Intellia Therapeutics' Next Hurdles After Its Positive Clinical Results ↗

July 11, 2021

There are still some key unanswered questions for the biotech's promising gene-editing therapy.

Via The Motley Fool

Mid-Cap Biotech Picks: Seasonal Rally Underway ↗

July 03, 2021

Many Mid-Cap biotech stocks were hit hard after the February peak. We suggest three new mid-cap biotech picks. All three picks can be volatile but very tradable.

Via Talk Markets

Stock Market Rally: S&P 500, Nasdaq Hit Highs; Facebook, Tesla, Nio, Intellia, Didi IPO, OPEC+ In Focus ↗

July 02, 2021

The S&P 500 and Nasdaq hit record highs last week. Facebook hit a $1 trillion market cap. Tesla deliveries jumped.

Via Investor's Business Daily

Topics Initial Public Offering Stocks

Here's What Drove Gene Editing Stocks Higher This Week ↗

July 02, 2021

The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.

Via The Motley Fool

'Halftime Report' Traders Share Their Thoughts On Crispr Therapeutics And Bed Bath & Beyond ↗

June 30, 2021

Amy Raskin said on CNBC's "Fast Money Halftime Report" that she would hold Crispr Therapeutics AG (NASDAQ: CRSP). She doesn't own the stock, but she owns...

Via Benzinga

Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar ↗

June 30, 2021

Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia.

Via InvestorPlace

Why Gene Editing Stocks Are Trading Higher Again Today ↗

June 30, 2021

Shares of gene editing stocks are continuing higher in sympathy with peer company Intellia (NASDAQ: NTLA), which gained in recent sessions following positive data for its...

Via Benzinga

44 Stocks Moving In Monday's Mid-Day Session ↗

June 28, 2021

Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software...

Via Benzinga

60 Biggest Movers From Yesterday ↗

June 29, 2021

Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its...

Via Benzinga

Intellia Stock Leads Biotech Rally On Historic Moment For CRISPR ↗

June 28, 2021

Intellia led a rally for CRISPR stocks on Monday on early promise for its gene-editing drug. The news sent NTLA stock to a record high.

Via Investor's Business Daily

Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks ↗

June 28, 2021

Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics.

Via InvestorPlace

24 Stocks Moving in Monday's Pre-Market Session ↗

June 28, 2021

Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim...

Via Benzinga

Crispr Therapeutics Stock Sees Improved Relative Strength Rating ↗

June 25, 2021

Crispr Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 68 to 74.

Via Investor's Business Daily

Gold Stocks On Sale ↗

June 20, 2021

In this video, we discuss our top stocks of the week, how gold is on sale, and how some market signals have been particularly troubling and misread.

Via Talk Markets

Healthcare Portfolio Playbook: Time To Rebalance With MedTech ↗

June 18, 2021

As we look to re-balance our portfolio in the near-term, investors should consider adding Medtech as we have suggested in the past. Though, more recently, we have also focused on large-cap...

Via Talk Markets

< Previous 1 2

...

29 30 31 32 33 34 35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.